Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2025: 11.06%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has an Asset Resilience Ratio of 11.06% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688505 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥280.00 Million

≈ $40.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.53 Billion

≈ $370.37 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2005–2022)

This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See what is Shanghai Fudan-Zhangjiang Bio-Pharmaceut's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai Fudan-Zhangjiang Bio-Pharmaceut.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥280.00 Million	11.06%
Total Liquid Assets	CN¥280.00 Million	11.06%

Asset Resilience Insights

Moderate Liquidity: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has 11.06% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Zhejiang Huahai Pharmaceutical Co Ltd SHG:600521	Drug Manufacturers - Specialty & Generic	0.44%
Emcure Pharmaceuticals Ltd NSE:EMCURE	Drug Manufacturers - Specialty & Generic	1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Ningbo Menovo Pharm Co Ltd SHG:603538	Drug Manufacturers - Specialty & Generic	2.69%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%

Annual Asset Resilience Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2022)

The table below shows the annual Asset Resilience Ratio data for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	1.12%	CN¥33.32 Million ≈ $4.88 Million	CN¥2.98 Billion ≈ $435.48 Million	+1.12pp
2011-12-31	0.00%	CN¥11.00K ≈ $1.61K	CN¥358.88 Million ≈ $52.52 Million	-0.04pp
2010-12-31	0.05%	CN¥143.00K ≈ $20.93K	CN¥304.15 Million ≈ $44.51 Million	+0.02pp
2006-12-31	0.03%	CN¥38.00K ≈ $5.56K	CN¥145.02 Million ≈ $21.22 Million	-0.31pp
2005-12-31	0.33%	CN¥475.00K ≈ $69.51K	CN¥142.91 Million ≈ $20.91 Million	--

pp = percentage points

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

SHG:688505 China Drug Manufacturers - Specialty & Generic

Market Cap

$824.00 Million

CN¥5.63 Billion CNY

Market Cap Rank

#10069 Global

#2875 in China

Share Price

CN¥8.01

Change (1 day)

-0.50%

52-Week Range

CN¥7.33 - CN¥11.12

All Time High

CN¥39.80